ANB032 — Atopic Dermatitis

In Q2 2023, we initiated a global Phase 2 trial of ANB032 for the treatment of moderate-to-severe atopic dermatitis

Top-line data are anticipated by year-end 2024

Th1, Th2, Th17, Th22 and dendritic cells in tissue and periphery drive atopic dermatitis pathogenesis

Adapted from Nature Reviews Disease Primers volume 4, Article number: 1 (2018).

Immune pathway skewing in atopic dermatitis patient populations highlights the need for new therapies

AD is highly heterogeneous involving multiple immune cytokines

  • Immune activation can vary by ethnicity resulting in a highly heterogeneous presentation
  • Substantial unmet need across all patient populations

Expect ANB032 to drive deeper responses across broader patient population

  • Restore immune balance

Adapted from Renert-Yuval Y, et al. Ann Allergy Asthma Immunol 2020;124:28–35; Czarnowicki T, et al. J Allergy Clin Immunol 2019;143:1–11

ANB032 inhibits Th1, Th2, Th17 and Th22 cytokine secretion more broadly than anti-OX40L in AD patient-derived PBMCs

Sanofi’s OX40L P2b AD data demonstrates impact on disease pathology beyond Th2; While ANB032 more broadly inhibits T cell cytokine secretion, it additionally modulates dendritic cells inducing Tregs

ANB032-treated DCs induce functional Tregs offering potential to restore immune balance

1. DCs were treated with either ANB032 or isotype and then co-cultured with allogenic naïve CD4 T cells to allow T cell differentiation. T cells were stained for CD4, CD25 and intracellular Foxp3 to identify inducible Tregs 2. Effect of ANB032-treated DCs on functional Tregs and inflammatory cytokine secretion in an MLR assay 3. Guttman-Yassky, et al. J Allergy Clin Immnol 2007;119:1210-7.